WARD MICHAEL RICHARDSON
Medical Practice in Pittsburgh, PA
License number
Pennsylvania MD447938
Category
Medicine
Type
Medical Physician and Surgeon
Address
Address
Pittsburgh, PA 15224
Personal information
See more information about WARD MICHAEL RICHARDSON at radaris.comName
Address
Phone
24 Hedgerow Ln, Malvern, PA 19355
1821 Marmaduke St, Pittsburgh, PA 15212
Professional information
Dr. Ward M Richardson, Pittsburgh PA - MD (Doctor of Medicine)
Specialties:
Pediatric Surgery
Address:
4401 Penn Ave, Pittsburgh 15224
Pittsburgh Office
4401 Penn Ave SUITE 2000, Pittsburgh 15224
(412) 692-5325 (Phone), (412) 692-6076 (Fax)
200 Lothrop St, Pittsburgh 15213
(412) 647-3389 (Phone), (412) 647-1999 (Fax)
MAGEE-WOMENS HOSPITAL DEPARTMENT OF NEW BORN MEDICINE
300 Halket St, Pittsburgh 15213
(412) 641-4111 (Phone), (412) 641-5313 (Fax)
Pittsburgh Office
4401 Penn Ave SUITE 2000, Pittsburgh 15224
(412) 692-5325 (Phone), (412) 692-6076 (Fax)
200 Lothrop St, Pittsburgh 15213
(412) 647-3389 (Phone), (412) 647-1999 (Fax)
MAGEE-WOMENS HOSPITAL DEPARTMENT OF NEW BORN MEDICINE
300 Halket St, Pittsburgh 15213
(412) 641-4111 (Phone), (412) 641-5313 (Fax)
Languages:
English
Education:
Medical School
University of Pittsburgh / Main Campus
Graduated: 2004
University of Pittsburgh / Main Campus
Graduated: 2004
Use Of Toll-Like Receptor-9 Agonists, Toll-Like Receptor-4 Antagonists, And/Or Nuclear Oligomerization Domain-2 Agonists For The Treatment Or Prevention Of Toll-Like Receptor-4-Associated Disorders
US Patent:
2008031, Dec 18, 2008
Filed:
Apr 17, 2008
Appl. No.:
12/104816
Inventors:
David J. Hackam - Pittsburgh PA, US
Ward M. Richardson - Pittsburgh PA, US
Steven C. Gribar - Monroeville PA, US
Alexander P. Ducruet - Pittsburgh PA, US
Ward M. Richardson - Pittsburgh PA, US
Steven C. Gribar - Monroeville PA, US
Alexander P. Ducruet - Pittsburgh PA, US
International Classification:
A61K 31/7084, A61K 39/395, A61K 38/12, A61K 38/05, A61P 31/04
US Classification:
4241301, 514 44, 514 11, 514 19
Abstract:
The present invention relates to the use of a TLR9 agonist and/or a TLR4 antagonist and/or a NOD2 agonist for treatment or prevention of disorders involving TLR4 activation, such as systemic sepsis and necrotizing enterocolitis.